Abstract
600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma
Journal for immunotherapy of cancer, Vol.13(Suppl 2), pp.A683-A683
11/01/2025
DOI: 10.1136/jitc-2025-SITC2025.0600
Abstract
BackgroundTreatment options for melanoma that has progressed on anti-PD-1 therapy are limited. Vusolimogene oderparepvec (RP1) is a fusion-enhanced HSV-1-based oncolytic immunotherapy. The IGNYTE trial showed that RP1 in combination with nivolumab (nivo) demonstrated clinically meaningful, durable responses (objective response rate, 32.9%; median duration of response, 33.7 months by RECIST 1.1) in patients with anti-PD-1-failed melanoma, with mainly grade 1/2 constitutional-type side effects. The trial allowed retreatment with RP1 for patients deriving clinical benefit. Here, we present the investigator assessment of patients who were retreated with RP1 in the IGNYTE trial.MethodsPatients with melanoma and confirmed progression on anti-PD-1 ± anti-CTLA-4 therapy for ≥8 weeks as the last prior treatment were enrolled. During the initial course, RP1 was given intratumorally at 1×106 PFU/mL initially, then at 1×107 PFU/mL Q2W (≤7 doses) with intravenous nivo (240 mg). Nivo was then given alone (240 mg Q2W or 480 mg Q4W) for 2 years. Retreatment with RP1 could occur if patients had injectable lesions, stable performance status, and no treatment-related grade 4 adverse events (AEs) or grade 3 injection-site reactions, infections, or immune-mediated AEs lasting >14 days. Additional doses of RP1 were administered at 1x107 PFU/mL Q2W either in combination with nivo or as monotherapy if nivo was stopped due to nivo-related toxicity. An investigator survey was performed to assess efficacy and safety in patients who received retreatment with RP1.ResultsOf 140 enrolled patients, 25 (18%) were retreated with RP1 after the first course of therapy (range, 1–24 additional doses). Of these, 17 patients experienced clinical benefit as determined by the investigator. Reasons for further treatment included aiming for deepening of response or delay of disease progression. Observed anti-tumor effects included complete resolution of new lesions (n = 1 patient) and deepened response (n = 4 patients). Five patients reported at least one grade ≥3 treatment-emergent AE, most of which were deemed not related to RP1.ConclusionsRetreatment with RP1 demonstrated investigator-assessed clinical benefit in the majority of patients to whom it was given (17/25 patients; 68%). Retreatment was well tolerated with the safety profile being consistent with that of the study overall. Additional clinical data from this collection of case reports will be presented.Trial RegistrationClinicalTrials.gov NCT03767348Ethics ApprovalThe study was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and was approved by the institutional review board/ethics committee at each participating site. Written informed consent was obtained from all patients prior to the conduct of any study-related procedures.
Details
- Title: Subtitle
- 600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma
- Creators
- Gino K InMichael Wong - Roswell Park Comprehensive Cancer CenterJoseph Sacco - Clatterbridge Cancer Centre NHS Foundation TrustEva Couselo - Vall d'Hebron Institut de RecercaDirk SchadendorfGeorgia Beasley - Duke UniversityJiaxin NiuBartosz ChmielowskiTrisha Wise-Draper - University of CincinnatiMohammed Milhem - University of IowaTawnya Bowles - Intermountain Medical CenterKaty Tsai - University of California, San FranciscoCéleste LebbéCaroline Gaudy-MarquesteAdel Samson - University of LeedsJunhong ZhuChris TucciMarcus VianaJeannie HouCaroline Robert - Institut Gustave Roussy
- Resource Type
- Abstract
- Publication Details
- Journal for immunotherapy of cancer, Vol.13(Suppl 2), pp.A683-A683
- DOI
- 10.1136/jitc-2025-SITC2025.0600
- eISSN
- 2051-1426
- Publisher
- BMJ Publishing Group LTD
- Language
- English
- Date published
- 11/01/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985024140302771
Metrics
2 Record Views